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The plasma disposition of cefoperazone was investigated after intravenous 
(IV) and intramuscular (IM) administrations of 20 mg/kg as a single dose in six 
camels (Camelus dromedarius) in a crossover design. Blood plasma samples were 
analysed by high-performance liquid chromatography (HPLC). After IV admin-
istration, elimination half-life (t1/2β), volume of distribution at steady state (Vdss), 
total body clearance (Cltot) and mean residence time (MRT) of cefoperazone were 
1.95 h, 0.38 L/kg, 0.17 L/h/kg and 2.16 h, respectively. After IM administration 
of cefoperazone, peak plasma concentration (Cmax) was 21.95 μg/mL and it was 
obtained at (tmax) 1.23 h. Absorption half-life (t1/2ab), elimination half-life and 
mean absorption time were 0.45 h, 2.84 h and 2.07 h, respectively. The bioavaila-
bility of cefoperazone was 89.42%. The lack of local reaction or any other ad-
verse effects and the very good bioavailability following IM administration indi-
cate that cefoperazone might be a promising alternative treatment for a variety of 
infectious diseases in camels. 
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Cefoperazone is a safe third-generation cephalosporin with few adverse ef-
fects, having broad-spectrum activity against Gram-positive, Gram-negative and 
anaerobic bacteria. Cefoperazone is very active against most strains of the family 
Enterobacteriaceae and Pseudomonas aeruginosa (Gupta et al., 2008). 
Pharmacokinetic studies of cefoperazone had been conducted in different 
animals such as sheep (Guerrini et al., 1985), calves (Carli et al., 1986), rabbits 
(Marino et al., 1987), unweaned calves (Soback and Ziv, 1989), horses (Soraci et 
al., 1996), dogs (Montesissa et al., 2003), buffalo calves (Goyal et al., 2005), 
cross-bred calves (Gupta et al., 2008), and goats (Attia et al., 2015). 
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No data on the pharmacokinetics of cefoperazone had been reported in 
camels. This study investigated the plasma disposition profile of cefoperazone 
after a single IV and IM administration of 20 mg/kg body weight in camels. 
 
 
Materials and methods 
Animals 
Six clinically healthy male camels (body weight: 400–500 kg, age: 6–7 
years) were used. Camels had not received any drug for at least two months be-
fore the study and were fed concentrates and hay, with water provided freely. 
The Ethics Committee of the Faculty of Veterinary Medicine, Cairo University, 
approved the use of camels and study protocols. 
Experimental design 
A crossover design (3 × 3) was used in this study; cefoperazone (20 mg/kg) 
was administered IV (3 camels; right jugular vein) or IM (3 camels; left neck 
muscles) to each camel as assigned. After a 2-week ‘washout’ period, camels 
that had been dosed IM with cefoperazone were injected IV, and vice versa. 
Cefoperazone was obtained as a sterile injectable powder (Cefobid®, cefopera-
zone sodium powder produced by SmithKline Beecham for Pfizer, Egypt) and 
dissolved in sterile saline immediately prior to administration. 
A 10-mL blood sample was collected from each camel by jugular veni-
puncture into tubes containing heparin from the left jugular vein at 0 min and at 
0.08, 0.16, 0.25, 0.5, 1, 2, 4, 6, 8, 12 and 24 h after administration. Blood sam-
ples were centrifuged at 3000 g for 15 min and the plasma was stored at –20 °C 
until analysis by high-performance liquid chromatography (HPLC). 
Analytical method 
Plasma cefoperazone concentrations were determined by HPLC according 
to Haghgoo et al. (1995). An HPLC system (Shimadzu Corporation, Kyoto, Japan) 
with a reverse-phase C18 analytical column (Whatman®, MA, USA, 4.60 × 100 mm 
internal diameter, particle size 5 μm) at room temperature was used for separa-
tion and reading at 266 nm wavelength using an UV detector (Shimadzu, SPD-
10A UV detector, Shimadzu Corporation). The mobile phase was 30 mM KH2PO4 
buffer and methanol (70:30, v/v) at a pH of 5.0. The mobile phase was filtered 
through 0.45 µm filters and was pumped into the column at a flow rate of 1.0 mL/ 
min at ambient temperature. Plasma samples (50 µl) were deproteinised by add-
ing a solution containing 50 µl of 10% perchloric acid and 50 µl of a mixture of 
acetonitrile (50%) and methanol (50%), and were mixed in a clean centrifuge 
tube by shaking on a vortex mixer for 1 min; after centrifugation at 10,000 g at 
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5 °C for 5 min, the clear supernatant was transferred to an autosampler vial and a 
20 μl aliquot was injected into the HPLC system. 
The calibration curves were performed between 0.5 and 200 µg/mL using 
blank camel plasma. The standard curve of cefoperazone was linear with a corre-
lation coefficient of 0.99. The retention time of cefoperazone in camel plasma 
was approximately 9.7 min. LOD was 0.1 μg/mL, LOQ was 0.5 μg/mL, and CV 
was < 15%. The mean percentage recovery values for cefoperazone in plasma 
samples spiked at concentrations of 1, 10 and 20 μg/mL were 98.37 ± 4.28%, 
97.19 ± 3.53% and 94.06 ± 3.41%, respectively. Intra-assay CV values ranged 
from 2.62 to 3.08% (n = 5, 3 times). The inter-assay CV varied from 3.49 to 
4.73% (n = 5, 3 times, 3 days). 
Pharmacokinetic analysis 
Plasma cefoperazone concentrations after IV and IM administrations were 
subjected to analysis using a computerised WinNonlin 6.3 program (Pharsight, 
Mountain View CA, USA). For IV and IM data, the appropriate pharmacokinetic 
model was determined by visual examination of individual plasma concentration 
versus time curves and by application of the Akaike information criterion 
(Yamaoka et al., 1978) resulting in the following two-compartmental model be-
ing chosen for data analysis. Half-lives were calculated using of the following 
equations: 
t1/2ab = ln(2)/kab 
t1/2α = ln(2)/α 
t1/2β = ln(2)/β, 
where kab, α, and β are the absorption, distribution and elimination rate 
constants, respectively. AUC and AUMC were calculated using the method of 
trapezoids with extrapolation to infinity (Gibaldi and Perrier, 1982). 
Absolute bioavailability (F) = AUCIM/AUCIV × 100; mean absorption time 
(MAT) = MRTIM – MRTIV. For IV data, Vdss was estimated as follows: Vdss = 
dose × AUMC/AUC2 and CL = dose/AUC. 
Statistical analysis 
The results obtained were displayed as mean ± SE. The paired t test was 
used to test for differences between the two administration routes. The statistical 
software SPSS version 16 (SPSS Inc., Chicago, USA) was used for statistical 
analysis and values of P < 0.05 were considered significant. 
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Results 
No side effects occurred after either of the two administrations routes in 
camels. Plasma concentration–time profiles of cefoperazone (20 mg/kg body 
weight) after single IV and IM administrations are presented in Fig. 1. The val-
ues of pharmacokinetic parameters estimated from the curve fitting are shown in 
Table 1. Following IV administration, t1/2α and t1/2β were 0.18 and 1.95 h, respec-
tively. Following IM administration the corresponding pharmacokinetic variables 
were t1/2ab 0.45 h, Cmax 21.95 µg/mL at tmax 1.23 h and t1/2β 2.84 h, while bioavail-
ability was 89.42%. 
 
Fig. 1. Semi-logarithmic graph depicting the time-concentration of cefoperazone in the plasma of 
camels after a single IV (○) and IM (■) administration of 20 mg/kg body weight (n = 6) 
 
 
Discussion 
Following IV administration, the disposition of cefoperazone followed a 
two-compartment open model, which is consistent with previous reports on 
cefoperazone in horses (Soraci et al., 1996) and dogs (Montesissa et al., 2003), 
and it was similar to the disposition of other cephalosporins in camels such as 
ceftiofur (Goudah, 2007), ceftriaxone (Goudah, 2008), cefepime (Goudah et al., 
2009), and ceftazidime (Goudah and Hasabelnaby, 2013).  
Cefoperazone has a short distribution half-life (t1/2α = 0.18 h). Similar find-
ings have been recorded in calves (0.15 h; Carli et al., 1986), dogs (Montesissa et 
al., 2003), longer than cefoperazone in horses (0.07 h; Soraci et al., 1996) and 
shorter than other cephalosporins in camels such as ceftiofur (0.3 h; Goudah, 
2007), ceftriaxone (0.27 h; Goudah, 2008), cefepime (0.3 h; Goudah et al., 
2009), and ceftazidime (0.3 h; Goudah and Hasabelnaby, 2013). 
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Table 1 
Plasma pharmacokinetic parameters (mean ± SE) of cefoperazone in camels following IV and IM 
administration of 20 mg/kg body weight (n = 6) 
Parameters Unit IV IM 
t1/2ab h – 0.45 ± 0.05 
t1/2α h 0.18 ± 0.02 0.54 ± 0.04** 
t1/2β h 1.95 ± 0.05 2.84 ± 0.13*** 
AUC μg mL–1 h–1 116.13 ± 6.31 103.65 ± 5.23*** 
AUMC μg mL–1 h–2 251.24 ± 12.01 444.49 ± 28.63*** 
MRT h 2.16 ± 0.03 4.26 ± 0.08*** 
MAT h – 2.07 ± 0.09 
Vdss L kg–1 0.38 ± 0.02 – 
Cltot L kg–1 h–1 0.174 ± 0.009 – 
Cmax μg mL–1 – 21.95 ± 0.68 
tmax h – 1.23 ± 0.04 
F % – 89.42 ± 1.74 
**P < 0.01;***P < 0.001; –: not calculated; t1/2ab: absorption half-life after IM administration; 
t1/2α: distribution half-life; t1/2β: elimination half-life; AUC: area under plasma concentration-
time curve; AUMC: area under moment curve; MRT: mean residence time; MAT: mean ab-
sorption time; Vdss: volume of distribution at steady state; Cltot: total body clearance; Cmax: 
maximum plasma concentration; tmax: time to peak plasma concentration; F: bioavailability 
 
The elimination half-life in camels (t1/2β) was 1.95 h. Similar findings were 
recorded for cefoperazone in dogs (1.40 h; Montesissa et al., 2003), for cefepime 
in camels (2 h; Goudah et al., 2009), longer than cefoperazone in calves (0.89 h; 
Carli et al., 1986), horses (0.77 h; Soraci et al., 1996) and shorter than other 
cephalosporins in camels such as ceftiofur (3.18 h; Goudah, 2007) and 
ceftazidime (2.85 h; Goudah and Hasabelnaby, 2013). 
The Vdss of cefoperazone was small (0.38 L/kg); this value is close to 
those reported for ceftriaxone in camels (0.32 L/kg; Goudah, 2008), higher than 
data reported for cefoperazone in sheep (0.16 L/kg; Guerrini et al., 1985), ceftio-
fur and cefepime in camels (0.13 L/kg and 0.1 L/kg, respectively; Goudah, 2007; 
Goudah et al., 2009), and lower than cefoperazone in horses (0.68 L/kg; Soraci et 
al., 1996) and unweaned calves (0.71 L/kg; Soback and Ziv, 1989). 
The total body clearance of cefoperazone was 0.17 L/h/kg. Similar find-
ings were reported for cefoperazone in sheep (0.11 L/h/kg; Guerrini et al., 1985). 
In contrast, a higher clearance of cefoperazone was recorded in horses (0.72 L/ 
h/kg; Soraci et al., 1996) and a lower clearance was recorded for ceftiofur and 
cefepime in camels (0.03 and 0.04 L/h/kg, respectively; Goudah, 2007; Goudah 
et al., 2009), and these differences could be correlated to interspecies differences 
in drug elimination and metabolism. 
The higher value of clearance of cefoperazone in camels suggests that 
there is negligible tubular reabsorption and cefoperazone is primarily excreted 
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through glomerular filtration. This finding is in agreement with the results re-
ported in humans (Barbhaiya et al., 1990). 
Species differences in pharmacokinetic parameters are relatively common 
and are frequently related to inter-species variation, the length of period between 
blood samplings, the assay method used, as well as the age and the health status 
of the animal (Haddad et al., 1985). 
After a single IM administration, cefoperazone was rapidly and efficiently 
absorbed in camels, as the t1/2ab was 0.45 h. This result was reasonably similar to 
that reported for cefoperazone in dogs (0.48 h; Montesissa et al., 2003) and long-
er than that reported for cefoperazone in horses (0.04 h; Soraci et al., 1996) and 
for ceftiofur and ceftriaxone in camels (0.34 and 0.29 h, respectively; Goudah, 
2007, 2008). The t1/2β of cefoperazone in camels was 2.84 h, which is longer than 
that reported in calves (0.79 h; Carli et al., 1986), horses (1.52 h; Soraci et al., 
1996), longer than that reported for ceftriaxone in camels (1.76 h; Goudah, 2008) 
and shorter than that reported for ceftiofur in camels (3.29 h; Goudah, 2007). The 
t1/2β after IM administration (2.84 h) was significantly longer than that obtained 
after IV administration (1.95 h). This difference is probably the result of contin-
ued absorption of cefoperazone from the IM injection site during the elimination 
phase, thereby prolonging the t1/2β of cefoperazone. 
The Cmax of cefoperazone after IM administration in camels was 21.95 μg/ 
mL, very similar to that observed for cefoperazone in dogs (24.5 μg/mL; Mon-
tesissa et al., 2003) and higher than that reported for cefoperazone in calves and 
horses (7.91 and 7.98 μg/mL, respectively; Carli et al., 1986; Soraci et al., 1996), 
and lower than that reported for ceftazidime in camels (32.43 μg/mL; Goudah 
and Hasabelnaby, 2013). The absorption process was rapid with a tmax of 1.23 h, 
which was similar to that of ceftiofur (1.22 h) and ceftazidime (1.21 h) in camels 
(Goudah, 2007; Goudah and Hasabelnaby, 2013). The MRT was longer after IM 
administration (4.26 h) than after IV dosing (2.16 h), as the MRT after IM ad-
ministration depends on both the disposition and absorption rates. 
The IM bioavailability was 89.42%, which is very similar to that of 
cefepime in camels (91.7%), higher than that of cefoperazone in calves (44.15%; 
Carli et al., 1986), horses (42%; Soraci et al., 1996), dogs (41.4%; Montesissa et 
al., 2003) and lower than that of ceftiofur in camels (97.4%; Goudah, 2007). 
The pharmacokinetics of many drugs has been found to be different in 
camels than in other animals. The species differences might be multifactorial and 
might depend on the metabolic rate of drugs (Ali et al., 1996). 
In conclusion, cefoperazone might be a promising alternative treatment for 
a variety of infectious diseases in camels due to its favourable pharmacokinetic 
profile. Further studies on tissue distribution and specific determination of the 
minimum inhibitory concentration (MIC) of cefoperazone for the major bacteria 
responsible for diseases in camels should be performed in order to obtain more 
complete efficacy data of cefoperazone in camels.  
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